Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. (31st December 2022)

• Record Type: Journal Article
• Authors: Deng, Min; Li, Shaohua; Wang, Qiaoxuan; Zhao, Rongce; Zou, Jingwen; Lin, Wenping; Mei, Jie; Wei, Wei; Guo, Rongping
• Is Part Of: Annals of medicine. Volume 54:Number 1(2022)
• Page Start: 803
• Page End: 811
• Publication Date: 2022-12-31
• Subjects: Intrahepatic cholangiocarcinoma -- immunotherapy -- PD-1 -- real-world -- outcome; Medicine -- Periodicals; 610
• DOI: 10.1080/07853890.2022.2048416
• Languages: English
• ISSNs: 0785-3890

Abstract

Abstract: Objective: There is a lack of effective treatment to improve the prognosis of intrahepatic cholangiocarcinoma (ICC). Programmed cell death protein-1 (PD-1)-targeted immunotherapy has shown promising results in a variety of malignant tumours. However, in patients with advanced ICC, the safety and efficacy of anti-PD-1 agents remain unclear. Methods: Forty-two advanced ICC patients treated with anti-PD-1 agents from August 2018 to December 2020 were retrospectively analyzed. Tumour response, overall survival (OS), progression-free survival (PFS), and time to tumour progression (TTP) were evaluated. Adverse events were also recorded. Results: The median duration of follow-up was 12.1 months, and the median time of treatment was 6.7 months for all patients. The median OS, median PFS, and median TTP for the whole cohort were 19.3 months, 11.6 months, and 11.6 months, respectively. The overall response rate (ORR) and disease control rate (DCR) for the whole cohort were 23.8% and 85.7%, respectively. Of the 42 evaluable individuals, two (4.8%) had hyperprogressive disease. The most common adverse events (AEs) were pain ( n = 6; 14.3%), anorexia ( n = 4; 9.5%), hypertension ( n = 4; 9.5%), pyrexia ( n = 3; 7.1%), cough ( n = 3; 7.1%), and hypothyroidism ( n = 3; 7.1%). The median OS of patients with albumin-bilirubin (ALBI) grade 1 was longer than that of patients with ALBI grade 2 (19.3 months vs. 14.7 months). The median PFS did not show a significant difference between ALBI grade 1 and grade 2 patients (13.6 months vs. 6.9 months). Conclusions: PD‐1‐targeted immunotherapy showed promising efficacy and safety in advanced ICC patients. Key messages: PD-1-targeted immunotherapy is a safe and effective treatment for advanced ICC patients. This study provides therapeutic strategy for advanced ICC patients.